Checkpoint Inhibitors, Hormonal Therapy, and CAR-T Cell Therapy

Correct Answer

C) Ipilimumab

Rationale

Ipilimumab is a fully human IgG1 monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte antigen 4), an inhibitory receptor expressed on activated T cells. Nivolumab and pembrolizumab are anti-programmed death 1 monoclonal antibodies. Durvalumab is an anti-programmed death ligand 1 monoclonal antibody.

Correct Answer

A) Pembrolizumab

Rationale

Pembrolizumab is a humanized IgG4 monoclonal antibody targeting programmed death 1, an inhibitory receptor expressed on effector T cells in the tumor microenvironment. Ipilimumab targets CTLA-4. Atezolizumab and durvalumab are anti-programmed death ligand 1 monoclonal antibodies that target the ligand rather than the receptor.

Correct Answer

D) Durvalumab

Rationale

Durvalumab is a monoclonal antibody targeting programmed death ligand 1, the ligand for the programmed death 1 receptor, approved for unresectable stage III non-small cell lung cancer after chemoradiotherapy. Pembrolizumab and nivolumab are anti-programmed death 1 antibodies that target the receptor. Ipilimumab targets CTLA-4.

Correct Answer

B) Tocilizumab

Rationale

Tocilizumab is a monoclonal antibody that blocks the interleukin-6 receptor, preventing IL-6 (interleukin-6) from binding and signaling. It is the first-line pharmacologic treatment for grade 2 and higher cytokine release syndrome after CAR-T cell therapy. Infliximab is an anti-TNF (tumor necrosis factor) antibody. Mycophenolate mofetil is a small molecule inhibitor of inosine monophosphate dehydrogenase. Ipilimumab targets CTLA-4.

Correct Answer

C) Enzalutamide

Rationale

Enzalutamide is a non-steroidal androgen receptor (AR) inhibitor that blocks testosterone and dihydrotestosterone binding to the androgen receptor, inhibits androgen receptor nuclear translocation, and prevents androgen receptor-mediated gene transcription. Abiraterone inhibits CYP17A1 (cytochrome P450 17A1), the enzyme that synthesizes androgens. Leuprolide is a GnRH (gonadotropin-releasing hormone) agonist. Anastrozole is an aromatase inhibitor.

Correct Answer

A) Abiraterone

Rationale

Abiraterone is a potent irreversible inhibitor of CYP17A1 (cytochrome P450 17A1; 17-alpha-hydroxylase/17,20-lyase), the enzyme responsible for androgen synthesis in the adrenal glands and intratumoral tissue. Enzalutamide is an androgen receptor inhibitor. Degarelix is a GnRH (gonadotropin-releasing hormone) antagonist. Letrozole is an aromatase inhibitor.

Correct Answer

A) CTLA-4 acts during T-cell priming in lymph nodes, where blocking it amplifies activation across many T-cell clones recognizing diverse antigens; programmed death 1 acts during the effector phase in the tumor microenvironment, producing more localized immune reactivation with fewer off-tumor effects

Rationale

CTLA-4 is expressed on T cells during the priming phase in lymph nodes, where it competes with CD28 for B7 ligands on antigen-presenting cells and suppresses the co-stimulatory signal required for full T-cell activation. Ipilimumab blocks this checkpoint during priming, releasing broad T-cell activation across many different antigen-specific clones — including clones reactive against self-antigens — which explains the diverse and more frequent immune-related adverse events compared to programmed death 1 blockade. Programmed death 1 acts at the effector phase within the tumor microenvironment, where its blockade restores function to T cells that have already been primed and trafficked to the tumor. This more localized mechanism produces a narrower immune-related adverse event spectrum. The IgG1 versus IgG4 distinction is real but does not explain the difference in immune-related adverse event breadth. Dose frequency differences do not account for the breadth difference. The statement about ipilimumab acting only on tumor-infiltrating T cells reverses the actual biology.

Correct Answer

D) Infliximab is itself hepatotoxic — it can cause liver enzyme elevation and drug-induced liver injury — making it an inappropriate choice when the liver is already inflamed by immune-related hepatitis

Rationale

Infliximab is an anti-TNF monoclonal antibody that carries a known risk of hepatotoxicity, including drug-induced liver injury and reactivation of hepatitis B virus. Using infliximab in the setting of immune-related hepatitis would add a hepatotoxic agent to an already inflamed liver, potentially worsening the hepatic injury. The steroid-sparing agent of choice for steroid-refractory immune-related hepatitis is mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase that suppresses lymphocyte proliferation without hepatotoxic risk. Infliximab is the correct steroid-sparing agent for steroid-refractory colitis, but this relationship is organ-specific. The mechanism is the drug's intrinsic hepatotoxic potential, not infusion reactions, and not a role for TNF in hepatitis resolution.

Correct Answer

D) Abiraterone inhibits CYP17A1, blocking androgen synthesis in the adrenal glands; this also blocks cortisol production, causing compensatory ACTH (adrenocorticotropic hormone) elevation that drives accumulation of upstream mineralocorticoid precursors, producing hypertension, hypokalemia, and fluid retention; prednisone suppresses ACTH and replaces cortisol

Rationale

CYP17A1 (17-alpha-hydroxylase/17,20-lyase) is the enzyme that converts pregnenolone to DHEA (dehydroepiandrosterone) and progesterone to androstenedione — the key step in androgen synthesis from cholesterol in the adrenal cortex, gonads, and intratumoral tissue. CYP17A1 is also required for cortisol synthesis. When abiraterone blocks CYP17A1, cortisol production falls, and the pituitary responds with compensatory ACTH release. The elevated ACTH drives adrenal steroidogenesis through pathways upstream of the CYP17A1 block, causing accumulation of mineralocorticoid precursors — particularly deoxycorticosterone and corticosterone — that produce hypertension, hypokalemia, and fluid retention. Prednisone suppresses ACTH through negative feedback and replaces cortisol, preventing these mineralocorticoid excess effects. This is not a bioavailability interaction, does not provide synergistic androgen receptor blockade, and is not an anti-emetic mechanism.

Correct Answer

B) Paroxetine is a potent inhibitor of cytochrome P450 2D6, the enzyme responsible for converting tamoxifen to endoxifen, its primary active metabolite; inhibiting this conversion reduces endoxifen plasma concentrations and may diminish tamoxifen's efficacy against breast cancer

Rationale

Tamoxifen is a prodrug that requires cytochrome P450 2D6 (CYP2D6)-mediated conversion to endoxifen, the metabolite responsible for the majority of tamoxifen's antiestrogenic activity in breast tissue. Paroxetine is a potent inhibitor of CYP2D6 and substantially reduces endoxifen plasma concentrations — studies show reductions of approximately 60 to 70 percent — which may diminish tamoxifen's efficacy against breast cancer recurrence. When hot flash management is required in a tamoxifen-treated patient, venlafaxine (a serotonin-norepinephrine reuptake inhibitor with minimal CYP2D6 inhibitory activity), gabapentin, or clonidine should be used instead of paroxetine or fluoxetine. Paroxetine inhibits CYP2D6, not induces it, so endoxifen levels fall rather than rise. It does not compete at the estrogen receptor. Tamoxifen metabolism is not primarily through CYP3A4.

Correct Answer

C) Tocilizumab blocks the IL-6 receptor peripherally but may elevate free IL-6 that crosses a disrupted blood-brain barrier; dexamethasone is the primary treatment for ICANS (immune effector cell-associated neurotoxicity syndrome) because it penetrates the central nervous system and directly suppresses neuroinflammation

Rationale

ICANS (immune effector cell-associated neurotoxicity syndrome) is a distinct toxicity of CAR-T therapy characterized by encephalopathy, aphasia, tremor, and in severe cases seizures and cerebral edema. Its pathophysiology involves CAR-T cell trafficking into the central nervous system, blood-brain barrier disruption, and cytokine-mediated neuronal injury. Tocilizumab, which blocks the IL-6 receptor peripherally, is not effective for ICANS and may paradoxically worsen it: by blocking peripheral IL-6 receptors, tocilizumab can increase free circulating IL-6 that then crosses the disrupted blood-brain barrier and drives central nervous system inflammation. Dexamethasone penetrates the blood-brain barrier and directly suppresses neuroinflammation, making it the treatment of choice for ICANS at all grades. When CRS and ICANS occur simultaneously — as in this patient who has both hypotension from CRS and neurological symptoms from ICANS — both tocilizumab (for CRS) and dexamethasone (for ICANS) should be given together.

Correct Answer

A) Leuprolide initially stimulates GnRH (gonadotropin-releasing hormone) receptors before causing receptor downregulation, producing a transient testosterone surge that can exacerbate bone pain and spinal cord compression in patients with skeletal metastases; bicalutamide blocks androgen receptor signaling during this flare period

Rationale

GnRH agonists such as leuprolide initially stimulate pituitary GnRH receptors, causing a surge in LH (luteinizing hormone) and FSH (follicle-stimulating hormone) release, which in turn drives a transient rise in testosterone — the testosterone flare — before sustained receptor downregulation leads to castrate levels after two to four weeks. In patients with bulky skeletal metastases or spinal involvement, this temporary testosterone surge can stimulate prostate cancer growth, worsening bone pain or precipitating spinal cord compression. Bicalutamide, an androgen receptor antagonist, blocks testosterone signaling at the receptor level during this flare period, preventing clinical deterioration without affecting the subsequent castration achieved by leuprolide. This antiandrogen cover is given only for the first four weeks. Leuprolide alone does achieve castration after downregulation; the co-administration is not required for castration itself, and the mechanism is not related to QTc prolongation or hepatic cytochrome P450 induction.

Correct Answer

C) Enzalutamide is a strong inducer of cytochrome P450 3A4, cytochrome P450 2C9, and cytochrome P450 2C19, substantially reducing plasma concentrations of drugs metabolized by these enzymes, including warfarin, direct oral anticoagulants, and most other oncology agents co-administered with enzalutamide

Rationale

Enzalutamide is a strong inducer of cytochrome P450 3A4 (CYP3A4), cytochrome P450 2C9 (CYP2C9), and cytochrome P450 2C19 (CYP2C19) at therapeutic doses. Enzyme induction increases the metabolic clearance of co-administered drugs that are substrates of these enzymes, substantially reducing their plasma concentrations. Clinically significant reductions occur with warfarin (increasing bleeding risk from underdosing, requiring international normalized ratio monitoring after enzalutamide initiation), direct oral anticoagulants, and multiple oncology agents including docetaxel. A complete medication review is required before enzalutamide is started and after any dose change to identify interactions requiring dose adjustment or substitution. Enzalutamide is an inducer, not an inhibitor, of CYP3A4 — it reduces, not raises, levels of co-administered CYP3A4 substrates. It is not a clinically relevant P-glycoprotein inhibitor or inhibitor of renal tubular secretion.

Correct Answer

B) Corticosteroids do not restore thyroid function in immune-related hypothyroidism because the thyroid gland has been permanently destroyed by the immune-related inflammatory process; unlike colitis or hepatitis, destroyed endocrine glands cannot regenerate

Rationale

Immune checkpoint inhibitor-associated endocrine adverse events differ in a critical way from other immune-related adverse events such as colitis, hepatitis, and pneumonitis. In those conditions, corticosteroids suppress the ongoing immune attack, allowing normal tissue to recover. Endocrine glands — the thyroid, pituitary, adrenal cortex, and pancreatic beta cells — cannot regenerate once destroyed by immune-mediated inflammation. Corticosteroids may be used during the acute inflammatory phase to reduce symptom severity or treat associated pain, but they do not and cannot restore glandular secretory function. The result is permanent hormone deficiency requiring lifelong replacement therapy: levothyroxine for hypothyroidism, hydrocortisone for adrenal insufficiency, and insulin for type 1 diabetes mellitus. This permanence is what distinguishes endocrine irAEs from all other irAE categories, where gland recovery is the expected outcome after immunosuppressive treatment.

Correct Answer

B) Tocilizumab, an anti-IL-6 receptor monoclonal antibody, because interleukin-6 is the primary cytokine driving cytokine release syndrome and blockade of its receptor rapidly reduces fever and hemodynamic instability

Rationale

This presentation — fever, hypotension requiring vasopressors, and hypoxia on day five after CAR-T infusion — is grade 3 to 4 cytokine release syndrome (CRS). CRS results from massive IL-6 (interleukin-6) release as CAR-T cells lyse tumor cells and recruit macrophages that amplify the cytokine cascade. Tocilizumab, an anti-IL-6 receptor monoclonal antibody, is the first-line pharmacologic treatment for grade 2 and higher CRS; it rapidly blocks IL-6 receptor signaling and reduces fever and hemodynamic compromise. For severe CRS unresponsive to tocilizumab, corticosteroids are added. Corticosteroids alone are not the initial treatment because they can impair CAR-T cell expansion and are reserved for refractory or very severe CRS. Infliximab targets TNF-alpha; TNF-alpha does not drive CRS and infliximab has no role in CRS management. Dexamethasone is the treatment for ICANS (immune effector cell-associated neurotoxicity syndrome), not CRS.

Correct Answer

D) Infliximab, an anti-TNF monoclonal antibody that is the preferred steroid-sparing agent for steroid-refractory immune-related colitis, with high efficacy and rapid onset

Rationale

Immune-related colitis from CTLA-4 inhibition resembles inflammatory bowel disease histologically, and infliximab — an anti-TNF (tumor necrosis factor) monoclonal antibody — is the established steroid-sparing agent for steroid-refractory grade 3 and 4 immune-related colitis. TNF-alpha drives mucosal inflammation in immune-related colitis, and infliximab produces high response rates and rapid symptom reduction in this setting. It does not appear to impair the antitumor activity of checkpoint inhibitors. Mycophenolate mofetil is the steroid-sparing agent for steroid-refractory immune-related hepatitis, not colitis — this organ-specific distinction is a critical prescribing rule. Adding oral prednisone to inadequate intravenous methylprednisolone is not an escalation strategy. Vedolizumab has been used in refractory cases but is not the established first-line steroid-sparing agent for immune-related colitis.

Correct Answer

A) Abiraterone inhibits CYP17A1, blocking cortisol synthesis in the adrenal cortex; compensatory ACTH (adrenocorticotropic hormone) elevation drives accumulation of mineralocorticoid precursors upstream of the blocked enzyme, causing hypertension, hypokalemia, and fluid retention; prednisone suppresses ACTH and replaces cortisol, preventing these mineralocorticoid excess effects and making it a mandatory, not optional, component of therapy

Rationale

CYP17A1 (17-alpha-hydroxylase/17,20-lyase) is required for the synthesis of both androgens and cortisol from cholesterol in the adrenal cortex. When abiraterone inhibits CYP17A1, cortisol production falls. The pituitary responds with compensatory ACTH release, which drives adrenal steroidogenesis through pathways upstream of the CYP17A1 block, causing accumulation of mineralocorticoid precursors including deoxycorticosterone and corticosterone. These precursors activate mineralocorticoid receptors and produce hypertension, hypokalemia, and fluid retention. Prednisone suppresses ACTH through negative feedback on the hypothalamic-pituitary-adrenal axis and provides cortisol replacement. This prevents the mineralocorticoid excess syndrome and maintains adrenal homeostasis. Stopping prednisone — even asymptomatically — removes this suppression and allows ACTH to rise, potentially causing the mineralocorticoid excess toxicity. Prednisone is not an anti-emetic, not required for abiraterone bioactivation, and does not synergize with androgen receptor blockade through glucocorticoid receptor cross-reactivity.

Correct Answer

C) Substitute venlafaxine for paroxetine; venlafaxine treats depression and hot flashes with minimal cytochrome P450 2D6 inhibition, preserving endoxifen formation and maintaining tamoxifen efficacy

Rationale

Tamoxifen is a prodrug requiring cytochrome P450 2D6 (CYP2D6)-mediated conversion to endoxifen, the primary active metabolite responsible for its antiestrogenic activity in breast tissue. Paroxetine is a potent CYP2D6 inhibitor that reduces endoxifen plasma concentrations by approximately 60 to 70 percent, potentially compromising tamoxifen's efficacy against breast cancer recurrence. The appropriate management is to substitute venlafaxine — a serotonin-norepinephrine reuptake inhibitor that effectively treats both depression and hot flashes but has minimal CYP2D6 inhibitory activity — for paroxetine, thereby preserving endoxifen formation and maintaining tamoxifen efficacy. Gabapentin and clonidine are alternatives for hot flashes alone. Continuing both drugs ignores a clinically meaningful pharmacokinetic interaction in a patient receiving adjuvant therapy with curative intent. Switching to an aromatase inhibitor would be inappropriate in a premenopausal woman without ovarian suppression, as aromatase inhibitors are not effective in the premenopausal setting where ovarian estrogen production is intact. Adding a selective estrogen receptor degrader alongside tamoxifen is not standard and does not address the interaction.